San Diego, CA -- (SBWIRE) -- 01/29/2018 -- An investigation was announced for investors in NASDAQ:HALO shares over potential securities laws violations by Halozyme Therapeutics, Inc..

Investors who purchased shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by Halozyme Therapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

O January 16, 2018, an abstract detailing a Phase IB/II randomized study of Halozyme's drug PEGPH20 as a treatment for pancreatic cancer in combination with the cancer drug mFFOX was published in connection with a scheduled presentation at the 2018 Gastrointestinal Cancers Symposium. The abstract's authors concluded that the "addition of PEGPH20 to mFFOX is not recommended for further study and appears to be detrimental" after noting that patients who used the combination experienced higher levels of diarrhea, fatigue, nausea, vomiting, and more than those who used mFFOX as a monotherapy.

Those who purchased shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com